P

Pharmathen

Develops generic drugs and delivery technologies

Product Quality Lifecycle Supervisor

Full-TimeUpdated on 10/15/2026
No salary listed
Senior
Bachelor's
Pallini, Greece
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Educational background in Chemical Engineering, Chemistry, Biological or Pharmaceutical sciences.
  • A minimum of 5 years of experience in product quality management.
  • Excellent written and spoken English.
  • Computer literacy.
  • Ability to prioritize tasks and meet deadlines.
  • Strong project management skills.
  • Broad knowledge and extensive experience with pharmaceutical quality systems.
  • Extensive knowledge of European Good Manufacturing Practices to ensure compliance with national and European standards and legislation.
  • Ability to solve problems effectively.
  • Initiative and creativity.
Responsibilities
  • Collaborate with the quality control team to ensure products are tested and meet established quality standards before release.
  • Implement and monitor inspection and testing processes to identify and address deviations from product specifications.
  • Lead investigations into product defects, determine root causes, and implement corrective actions to prevent recurrence.
  • Identify opportunities to improve product quality and lead initiatives to enhance production processes and reduce defects.
  • Ensure products comply with current Good Manufacturing Practices, relevant industry standards, and regulatory requirements to support product release.
  • Maintain detailed records of quality control activities and prepare reports on product quality performance for management review.
  • Work with production, research and development, and supply chain teams to integrate quality standards throughout product development and manufacturing.
  • Train staff on quality standards and industry best practices.
  • Follow the Company's Quality Policy and comply with current operational standards and legislative requirements.
  • Own activities related to process validation, cleaning validation, out-of-specification and out-of-trend investigations, statistical evaluations, studies, annual product quality reviews, and stability oversight.
  • Participate in standard operating procedure and master record preparation and review, deviation handling, complaint management, document management, the training system, audit management including self-inspection, risk management, escalation processes, key performance indicator monitoring, change management, corrective and preventive actions, aseptic process simulation, utilities and environmental monitoring, other quality management system policies, site quality operations oversight, data integrity campaigns, and transfer and engineering projects.

About the company

Pharmathen develops generic medicines and advanced drug-delivery technologies from its Greece-based manufacturing sites, exporting to branded pharmaceutical companies and patients worldwide. Its products include long-acting injectables, sustained-release formulations, and ophthalmic drugs, built on a strategy of Life Cycle Management and new technology platforms. The company operates with full vertical integration, handling research, development, manufacturing, and export, under facilities approved by the US FDA and EU. This enables it to deliver high-quality generic solutions and optimized dosage forms at scale. Pharmathen differentiates itself through a focused emphasis on drug-delivery platforms, continuous pipeline development, and end-to-end control over development and manufacturing. Its goal is to provide high-quality, affordable medicines while expanding its capabilities in innovative generic products and advanced delivery technologies for global markets.

Company Size

501-1,000

Company Stage

Acquired

Total Funding

N/A

Headquarters

Athens, Greece

Founded

1969

Get referred to Pharmathen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Neuraxpharm's December 2024 alliance creates Europe-wide commercialization for Pharmathen's LAI pipeline.
  • CBL Patras acquisition expands peptide capacity and adds an FDA-approved manufacturing base.
  • NTC bought Pharmathen's ophthalmology unit, proving monetizable assets despite operational turmoil.

What critics are saying

  • FDA issued a 2026 warning letter and import alert over sterile manufacturing failures.
  • Reuters reported August 2026 paliperidone shortages from Pharmathen disruptions, hitting schizophrenia patients across Europe.
  • Partners Group wrote Pharmathen equity to zero in June 2026, signaling debt-driven distress and possible restructuring.

What makes Pharmathen unique

  • Pharmathen pairs drug-delivery R&D with in-house manufacturing across Greece and Europe.
  • Its 2024 Neuraxpharm pact locked Pharmathen into psychiatry long-acting injectables globally.
  • CBL Patras added FDA-approved peptide manufacturing, strengthening complex sterile capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

12%

1 year growth

12%

2 year growth

12%
PR Newswire
Dec 10th, 2025
NTC acquires Pharmathen's ophthalmology business, reaching €100M revenue with Wise Equity backing

NTC, an Italian pharmaceutical company specialising in ophthalmology, has completed the acquisition of Pharmathen's ophthalmology business unit with support from its main shareholder Wise Equity. The deal adds a consolidated portfolio of glaucoma treatments to NTC's offerings. The acquisition brings NTC's revenue to approximately €100 million, with over 80% derived from ophthalmology. The company now reaches more than 100 countries through over 250 distribution partners and gains entry into the US market through its B2B model. The acquired glaucoma portfolio includes many preservative-free formulations and complements NTC's existing therapeutic areas covering antibiotic therapy, inflammation, allergies and dry eye. Globally, around 80 million people suffer from glaucoma, a number expected to reach 112 million by 2040. Wise Equity's Wisequity VI fund, launched in May 2023 with €400 million in commitments, supported the transaction.

World Pharmaceutical Frontiers
Dec 13th, 2024
Neuraxpharm and Pharmathen partner to develop LAI psychiatry therapies

Neuraxpharm and Pharmathen have signed a co-development agreement to develop long-acting injectable (LAI) therapies for the psychiatry sector.

PR Newswire
Dec 12th, 2024
Neuraxpharm And Pharmathen Enter Into Strategic Co-Development Agreement To Develop Long-Acting Injectable Therapies

New therapies will allow patients greater choice and flexibility in the control of CNS disorders. BARCELONA, Spain, DÜSSELDORF, Germany, and ATHENS, Greece, Dec. 12, 2024 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and Pharmathen, one of the largest pharmaceutical companies in Greece and leaders in the development and supply of long-acting injectable (LAI) therapies, announce a strategic alliance to co-develop new long-acting injectable therapies within the psychiatry field under Pharmathen's long-acting therapeutic technologies (LATT) program. Under this agreement, Neuraxpharm will have exclusive rights to commercialise these therapies in Europe, and in countries outside of Europe where the group has a direct presence, while Pharmathen will have exclusive rights for North America and all other countries not covered by Neuraxpharm

Financial Times
Jun 30th, 2024
Swiss buyout firm Partners Group lands deal for stake in €900mn biotech firm

The buyout fund bought Greece-based generics manufacturer Pharmathen in 2021 for €1.6bn including debt and last year invested alongside GHO in drug manufacturing outsourcer Sterling Pharma Solutions.

Ropes & Gray
Nov 6th, 2023
Ropes & Gray Advises Pharmathen on Acquisition of CBL Patras

Ropes & Gray has advised Pharmathen, a leading European complex drug delivery and formulation developer, on its acquisition of CBL Patras, a leading vertically integrated and US-FDA approved peptide manufacturer and supplier in Europe.